After gathering all the encouraging in vitro data presented before, which demonstrate the potential of using UniCAR T-cells in combination with αFAP TMs to specifically eradicate FAP-expressing tumor cells, the next step was to evaluate the immunotherapeutic effect of such a platform using a mouse model. This evidence concerns the gene AFAP1 and neoplasm.